Lantern Pharma (LTRN) investor relations material

AI-driven drug development and platform strategy

• Focus on developing cancer therapies using a proprietary AI platform, with three drugs in clinical trials and over 10 programs launched in two years.

• AI platform compresses drug development timelines, increases clinical trial success odds, and enables both internal and collaborative drug discovery.

• Business model includes rescuing/repositioning drugs and developing novel molecules, with a unique dual engine strategy for monetizing both molecules and AI platforms.

• Subsidiary Starlight Therapeutics targets precision neuro-oncology, holding Fast Track designation for brain cancers.

• AI tools like predictBBB.ai and withZeta are now publicly accessible, enabling external researchers to leverage the platform for rare cancer drug development.

Clinical pipeline highlights

• LP-300 targets never smokers with lung cancer, showing an 86% clinical benefit rate and complete responses in early cohorts; phase II data to be presented at AACR.

• LP-184 is a novel, first-in-human drug for solid tumors, including triple-negative breast cancer and PTGR1-positive bladder cancer, with multiple FDA designations and strong biomarker-driven results.

• LP-284, developed for blood cancers and adult soft tissue sarcoma, demonstrated a complete metabolic response in the first lymphoma patient and holds orphan designations.

• Starlight Therapeutics has completed phase Ia enrollment for a brain cancer drug and is advancing to phase Ib/II, with all Lantern shareholders participating in its upside.

Platform validation and market opportunity

• AI platform validated through collaborations with leading academic institutions and external biotech partners, with equity and patent stakes in partner successes.

• Platform enables rapid, mechanistically validated drug development, with published results and patents supporting its capabilities.

• withZeta and predictBBB.ai tools open a $15–20 billion market opportunity by providing real-time, agentic drug design and analysis for rare cancers.

• Platform is already generating revenue through subscriptions and is positioned as a co-scientist for the broader pharma and biotech community.